Share Share on Facebook Share on Twitter Pinterest Email Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial Download the PDF here. This post appeared first on investingnews.com 0 Related Posts Completion of QSM Acquisition December 24, 2024 Don Hansen: Gold, Silver Stocks “Extraordinarily Undervalued,” Data Shows What’s Next December 24, 2024 Fortune Minerals Announces Second Draw From Convertible Securities Agreement With The Lind Partners December 23, 2024
Don Hansen: Gold, Silver Stocks “Extraordinarily Undervalued,” Data Shows What’s Next December 24, 2024
Fortune Minerals Announces Second Draw From Convertible Securities Agreement With The Lind Partners December 23, 2024